恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

deb-ag捕鱼平台

文字: 2017-7-27    浏览次数:1051    


safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma



deb-tace治疗进展期肝细胞癌的临床疗效和安全性



background:according to the barcelona clinic liver cancer (bclc) algorithm, patients with advanced stage (bclc-c) hepatocellular carcinoma (hcc) are recommended for systemic treatmentor palliative therapy. however, chemoembolization with drug-eluting beads (deb-tace) has been shown to be safe in high-risk patients. the purpose of our study was to evaluate the safety and effectiveness of deb-tace in patients with an advanced-stage hcc. 

        根据巴塞罗那临床肝癌分期(bclc),进展期(bclc-c)肝细胞癌(hcc)患者推荐采用全身治疗或姑息疗法。然而,已有研究显示基于可载药微球的化疗栓塞术(deb-tace)对于高风险患者安全性较好。本研究旨在评估deb-tace治疗进展期hcc患者的临床疗效和安全性。



methods:in this institutional review board-approved, retrospective study, 80 patients with advanced-stage hcc underwent deb-tace with doxorubicin. patients were evaluated for median hospital stay, incidence of grade 3/4 toxicities, 30-day mortality, progression-free survival (pfs), and overall survival (os) following deb-tace. univariate and multivariate analysis were performed for predictors of better os. 

      经机构审查委员会批准,本研究回顾性纳入80例曾行deb-tace(加载阿霉素)的进展期hcc患者。评估患者deb-tace术后的中位住院时间、3/4级毒性反应的发生率、30天内的死亡率、无进展生存期(pfs)和总生存期(os)。通过单变量和多变量分析寻找获得更长os的独立预测因子。


results:the median hospital stay following deb-tace was 1 day (range: 1–11). the median pfs and os were 5.1 months [95 % confidence interval (ci): 4.1–7.7] and 13.3 months (95 % ci:10.1–18.6) respectively. on multivariate analysis ecog ps b 1 and 2 deb-tace procedures were associated with better os. patients with ecog ps b 1 demonstrated a median survival of 17.7 months compared with 5.6 months for patients with ecog ps 1 ( p= 0.025). multiple deb-tace procedures (2 procedures) were associated with improved survival (26.8 months) compared with patients with one or two procedures (11.4 months, p = 0.01). portal vein thrombosis or extrahepatic disease had no statistically significant association with os.

        deb-tace术后患者的中位住院时间为1天(范围:1-11天)。中位pfs和os分别为5.1个月【95 %置信区间(ci):4.1–7.7】和13.3个月(95% ci:10.1–18.6)。通过多变量分析得出ecog ps≤1且>2次deb-tace与获得更长os有相关性。ecog ps ≤ 1的患者的中位生存期为17.7个月,而ecog ps > 1的患者的中位生存期为5.6个月(p=0.025)。相较仅行1或2次deb-tace患者(11.4个月),行多次deb-tace患者(> 2次)的生存期更长(26.8个月,p=0.01)。门静脉血栓或肝外疾病在统计学上与os无显著相关性。 


conclusions:deb-tace is safe and effective in patients with advanced hcc. ecog ps b 1 and 2 deb-tace procedures were associated with better os.

deb-tace在治疗进展期hcc患者方面安全有效。患者ecog ps≤1且deb-tace次数>2次利于获得更长os。